{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-21-040412","form_type":"8-K","ticker":"TARA","cik":"0001359931","company_name":"Protara Therapeutics, Inc.","filed_at":"2021-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:04:17.825297+00:00","generated_at":"2026-06-29T21:24:52.062306+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Protara Q2 net loss $12.8M; cash $145M; on track for TARA-002 IND by year-end","bullets":["Cash $145M; net loss $12.8M ($1.14/sh) vs $7.1M ($1.22/sh) in Q2 2020.","R&D expense rose to $5.9M (from $2.5M) on TARA-002; G&A $6.9M (from $4.8M).","Completed IND-enabling studies for TARA-002 in NMIBC; on track to file IND H2 2021 & start Phase 1.","GMP comparability for TARA-002 on track for year-end; seeking FDA alignment on LM trial design.","Appointed Dr. Jane Huang (BeiGene CMO) to Board of Directors in June 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-21-040412","json":"https://secwatch.observer/filing/0001213900-21-040412.json","markdown":"https://secwatch.observer/filing/0001213900-21-040412.md","text":"https://secwatch.observer/filing/0001213900-21-040412.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1359931/000121390021040412/0001213900-21-040412-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1359931/000121390021040412/ea145229-8k_protara.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T21:24:52.062306+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}